Mindset Pharma Expands IP Portfolio Identifying 3 New Families of Next-Generation Psychedelic Compounds

Drug discovery and development company Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) announced today the company has identified three additional families of highly novel, non-tryptamine, next-generation psychedelic compounds through its discovery work. The company which focuses on creating novel, optimized, next-generation psychedelic and non-psychedelic medications to treat neuropsychiatric and neurological disorders with unmet medical needs, Mindset announced in a press release that through the usage of fragment-based drug discovery (FBDD) method combined with a highly focused medicinal chemistry strategy, Mindset’s scientists designed and developed three new, chemically distinct, small molecule non-tryptamine scaffolds, Families 6, 7, and 8. The company The post Mindset Pharma Expands IP Portfolio Identifying 3 New Families of Next-Generation Psychedelic Compounds appeared first on Psychedelic Chronicle.